Table 1

Baseline anthropometric, pulmonary and clinical data, alongside differences between sexes and antifibrotic medication status, in 26 people with interstitial lung disease

VariableAll
(n=26)
Male
(n=19)
Female
(n=7)
P valueESAnti-fibrotics (n=13)No anti-fibrotics
(n=13)
P valueES
Age (years)70.3±7.771.0±8.468.4±5.00.350.3470.2±7.970.4±7.80.960.03
Height (cm)171±7173±6163±60.0011.67169±6173±80.160.57
Mass (kg)80.5±13.982.4±14.175.3±13.20.260.5174.3±11.086.7±14.10.0190.98
BMI (kg/m2)27.6±3.827.3±3.828.1±4.10.660.2126.1±3.329.0±3.80.0460.81
Body fat (%)36.8±10.132.9±8.547.2±5.9<0.0011.8035.7±10.237.8±10.20.600.21
Fat mass (kg)29.9±10.127.8±10.335.6±7.60.080.8026.6±8.833.2±10.60.100.68
Fat free mass (kg)50.6±10.154.6±7.539.7±8.0<0.0011.9547.7±9.853.6±9.90.140.60
FEV1 (L)2.40±0.542.57±0.46*1.88±0.46*0.0051.502.27±0.60§2.50±0.480.300.43
FEV1 (%Predicted)86.4±14.686.8±15.1*85.3±14.5*0.840.1082.5±14.6§89.7±14.40.240.50
FVC (L)3.06±0.773.31±0.66*2.31±0.58*0.0031.562.97±0.77§3.13±0.790.620.20
FVC (%Predicted)84.2±16.784.1±16.585.3±14.50.960.0778.5±13.089.8±18.60.090.70
FEV1/FVC0.79±0.080.78±0.09*0.82±0.40*0.340.190.77±0.110.81±0.060.310.46
DLCO (mL/min/kPa)4.48±1.094.65±1.20$3.98±0.41§0.240.624.33±1.44$4.61±0.74§0.580.25
DLCO (%Predicted)54.8±12.954.8±14.654.5±5.70.960.0254.1±17.555.4±7.40.810.10
GAP Score4±13±15±1*0.0032.004±1*4±10.740.00
 Diagnosis
 IPF
 UIP
 CHP
 Probable IPF
 Organising pneumonia
19
2
3
1
1
13
2
2
1
1
6
0
1
0
0
12
0
0
1
0
7
2
3
0
1
  • All continuous variables reported as mean±SD. Categorical data presented as whole numbers.

  • Significant differences (p<0.05) and large effect sizes (≥0.8) between groups highlighted in bold.

  • Unequal groups for variables: *=n-1, §=n-2, $=n-4.

  • BMI, body mass index; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia; CHP, chronic hypersensitivity pneumonitis; PFT, pulmonary function test; CPET, cardiopulmonary exercise test; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; DLCO, diffusion capacity for carbon monoxide; GAP, gender-age-physiology score; ES, effect size.